A Phase I Study of GC101 TIL in Advanced Solid Tumors

Clinical trial NCT05417750 · COMPLETED

Trial details

NCT number: NCT05417750
Sponsor: Shanghai Juncell Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Tumor Infiltrating Lymphocytes Safety Advanced Solid Tumor Immunotherapy Efficacy Adverse Drug Event

Start date: 2022-10-12
Primary completion: 2025-04-30
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.